Brainstorm Cell Therapeutics Inc.
BCLI
$0.69
$0.00-0.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.95% | -32.60% | -28.53% | -26.71% | -34.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.88% | -18.11% | -26.98% | -34.40% | -45.46% |
| Operating Income | 14.88% | 18.11% | 26.98% | 34.40% | 45.46% |
| Income Before Tax | 11.32% | 23.77% | 10.18% | 28.63% | 32.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.32% | 23.77% | 10.18% | 28.63% | 32.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.32% | 23.77% | 10.18% | 28.63% | 32.39% |
| EBIT | 14.88% | 18.11% | 26.98% | 34.40% | 45.46% |
| EBITDA | 14.83% | 18.09% | 27.14% | 34.70% | 45.91% |
| EPS Basic | 49.03% | 56.59% | 45.89% | 58.32% | 61.53% |
| Normalized Basic EPS | 49.03% | 56.59% | 45.89% | 58.32% | 61.52% |
| EPS Diluted | 49.03% | 56.59% | 45.89% | 58.32% | 61.74% |
| Normalized Diluted EPS | 49.03% | 56.59% | 45.89% | 58.32% | 61.52% |
| Average Basic Shares Outstanding | 84.37% | 77.88% | 68.16% | 65.62% | 74.91% |
| Average Diluted Shares Outstanding | 84.37% | 77.88% | 68.16% | 65.62% | 74.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |